cemdisiran   Click here for help

GtoPdb Ligand ID: 14708

Synonyms: AD-62643 | ALN-62643 | ALN-CC5
Immunopharmacology Ligand
Compound class: Nucleic acid
Comment: Cemdisiran is a small interfering RNA (siRNA) that is intended to reduce complement component 5 (C5) production. The molecule is N-acetylgalactosamine (GalNAc) modified to enhance hepatic delivery via binding to liver-expressed asialoglycoprotein receptors (ASGRs).

Cemdisiran is a 1:1 complex of

RNA1 (Am-sp-Am-sp-(2′-deoxy-2′-fluoro)G-Cm-(2′-deoxy-2′-fluoro)A-Am-(2′-deoxy-2′-fluoro)G-Am-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)U-Um-Um-(2′-deoxy-2′-fluoro)A-Um-(2′-deoxy-2′-fluoro)A-Am-Um-Am), 3′-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate] and

RNA2 (Um-sp-(2′-deoxy-2′-fluoro)A-sp-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)A-Um-Am-(2′-deoxy-2′-fluoro)A-Am-(2′-deoxy-2′-fluoro)A-Am-Um-Am-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)G-Cm-Um-Um-sp-Um-sp-Um-dT-dT)
No information available.
Summary of Clinical Use Click here for help
Cemdisiran was progressed as a clinical candidate with potential anti-inflammatory activity.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05744921 A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works Phase 3 Interventional Regeneron Pharmaceuticals
NCT06541704 A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy Phase 3 Interventional Regeneron Pharmaceuticals
NCT07154745 A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently Phase 3 Interventional Regeneron Pharmaceuticals